biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > The Biodexa Presentation for Roadshows

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Dec 14, 2022 4:06pm

121 Views

Post# 35171728

RE:RE:The Biodexa Presentation for Roadshows

It wouldn't make sense, pof, for Biodexa to use the xB3 name for anything if they're going to sell the xB3 program off.

I believe that's what this play is all about, to get xB3 into other hands for next to nothing.

jd

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec